Coherus BioSciences, Inc. (CHRS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Liquidia Corp.

Coherus BioSciences, Inc.

SIGA Technologies, Inc.

Marinus Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

Zymeworks, Inc.

Nurix Therapeutics, Inc.

Cullinan Therapeutics, Inc.

Oculis Holding AG

Procaps Group SA

Icosavax, Inc.

Why is Coherus BioSciences, Inc. ?

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -11.76%, its profits have fallen by -444.5%

Below par performance in long term as well as near term

Along with generating -11.76% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Coherus BioSciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Coherus BioSciences, Inc.

-11.76%

-0.27

81.89%

S&P 500

15.36%

1.17

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-38.41%

EBIT Growth (5y)

-202.75%

EBIT to Interest (avg)

-5.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.17

Sales to Capital Employed (avg)

0.91

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

53.70%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.00

EV to EBIT

-0.70

EV to EBITDA

-0.71

EV to Capital Employed

-2.15

EV to Sales

2.97

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-296.69%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

OPERATING PROFIT MARGIN(Q)

Highest at -219.96 %

RAW MATERIAL COST(Y)

Fallen by -13.13% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 3.82 times

NET SALES(Q)

Highest at USD 14.31 MM

OPERATING PROFIT(Q)

Highest at USD -31.47 MM

PRE-TAX PROFIT(Q)

Highest at USD -33.35 MM

NET PROFIT(Q)

Highest at USD -33.35 MM

EPS(Q)

Highest at USD -0.13

-9What is not working for the Company

NET SALES(9M)

At USD 39.37 MM has Grown at -45.32%

OPERATING CASH FLOW(Y)

Lowest at USD -186.04 MM

CASH AND EQV(HY)

Lowest at USD 272.35 MM

DEBT-EQUITY RATIO (HY)

Highest at -84.04 %

Here's what is working for Coherus BioSciences, Inc.

Operating Profit Margin

Highest at -219.96 % and Grown

In each period in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Net Sales

Highest at USD 14.31 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Net Sales

At USD 14.31 MM has Grown at 22.07%

over average net sales of the previous four periods of USD 11.72 MM

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -31.47 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -33.35 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -33.35 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.13

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Highest at 3.82 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -13.13% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Coherus BioSciences, Inc.

Operating Cash Flow

Lowest at USD -186.04 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Cash and Eqv

Lowest at USD 272.35 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -84.04 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio